Abstract：
Gout is a chronic joint disease caused by the deposition of monosodium urate crystals into and around the articular tissues. In the last two years, new insights regarding diagnosis, genetic involvement, pathogenesis, comorbidities, and clinical data, have allowed the identification of new strategies to improve the control of the disease and its flares. In keeping, the discover of new mechanisms concerning crystal-induced inflammation have suggested new ways for the management not only of gout, but also other systemic diseases, mainly including renal and cardiovascular disorders. In this context it is very representative the case of colchicine which, given the surprising results obtained both in laboratory and clinical experiments, has recently received by FDA the approval for the prevention of cardiovascular disorders.
摘要：
痛风是由尿酸单钠晶体沉积到关节组织中及其周围引起的慢性关节疾病。在过去的两年里,关于诊断的新见解，遗传参与，发病机制，合并症,和临床数据，已经允许确定新的策略来改善对疾病及其耀斑的控制。为了保持，关于晶体诱导炎症的新机制的发现不仅为痛风的治疗提供了新的方法，还有其他全身性疾病，主要包括肾脏和心血管疾病。在这种情况下，秋水仙碱的情况是非常有代表性的，鉴于在实验室和临床实验中获得的令人惊讶的结果，最近获得了FDA用于预防心血管疾病的批准。
